- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05487235
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase Ib, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of GDC-1971 when administered in combination with atezolizumab in participants with locally advanced or metastatic solid tumors.
The study will have 2 stages- dose finding stage and expansion stage. In expansion stage participants with non-small cell lung cancer programmed death ligand -1 high (NSCLC PD L-1 high), NSCLC PD L-1 low, head and neck squamous cell carcinoma (HNSCC) PD L-1 positive, BRAF wild type (BRAF WT) melanoma and any locally advanced or metastatic solid tumors will be enrolled.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: GO43712 https://forpatients.roche.com/
- Phone Number: 888-662-6728 (U.S. Only)
- Email: global-roche-genentech-trials@gene.com
Study Locations
-
-
-
Cordoba, Argentina, X5000JHQ
- Recruiting
- Sanatorio Allende
-
La Rioja, Argentina, F5300COE
- Recruiting
- Fundación CORI para la Investigación y Prevención del Cáncer
-
Rosario, Argentina, S2013SBK
- Recruiting
- Centro Medico IPAM
-
-
-
-
New South Wales
-
Darlinghurst, New South Wales, Australia, 2010
- Recruiting
- St Vincent'S Hospital Sydney
-
Wodonga, New South Wales, Australia, 3690
- Recruiting
- Border Medical Oncology
-
-
South Australia
-
Bedford Park, South Australia, Australia, 5042
- Recruiting
- Flinders Medical Centre
-
-
Victoria
-
Heidelberg, Victoria, Australia, 3084
- Recruiting
- Austin Hospital
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Recruiting
- One Clinical Research Perth
-
-
-
-
MG
-
Belo Horizonte, MG, Brazil, 30150-221
- Recruiting
- Santa Casa de Misericordia de Belo Horizonte - PPDS
-
-
PA
-
Curitiba, PA, Brazil, 81520-060
- Recruiting
- Liga Paranaense de Combate ao Cancer - Hospital Erasto Gaertner
-
Porto Alegre, PA, Brazil, 90035-903
- Recruiting
- Hospital de Clinicas de Porto Alegre HCPA PPDS
-
-
RS
-
Caxias Do Sul, RS, Brazil, 95070-561
- Recruiting
- Universidade de Caxias do Sul
-
Ijuí, RS, Brazil, 98700-000
- Recruiting
- ONCOSITE Centro de Pesquisa Clínica Em Oncologia
-
-
SP
-
JAU, SP, Brazil, 17210-080
- Recruiting
- Fundação Doutor Amaral Carvalho - Hospital Amaral
-
Sao Jose Do Rio Preto, SP, Brazil, 15090-000
- Recruiting
- Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS
-
Sao Paulo, SP, Brazil, 01246-000
- Recruiting
- Instituto do Cancer do Estado de Sao Paulo - ICESP
-
São Paulo, SP, Brazil, 03102-006
- Recruiting
- Instituto Brasileiro de Controle do Cancer Ibcc
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Recruiting
- Cross Cancer Institute
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Recruiting
- Ottawa Hospital
-
Toronto, Ontario, Canada, M5G 1Z5
- Recruiting
- Princess Margaret Cancer Centre
-
-
-
-
-
Cheongju si, Korea, Republic of, 28644
- Recruiting
- Chungbuk National University Hospital
-
Goyang-si, Korea, Republic of, 10408
- Recruiting
- National Cancer Center
-
Seoul, Korea, Republic of, 03080
- Recruiting
- Seoul National University Hospital
-
Seoul, Korea, Republic of, 03722
- Recruiting
- Severance Hospital, Yonsei University Health System
-
Seoul, Korea, Republic of, 05505
- Recruiting
- Asan Medical Center - PPDS
-
Seoul, Korea, Republic of, 6591
- Recruiting
- The Catholic University of Korea Seoul St. Mary?s Hospital
-
Suwon-si, Korea, Republic of, 16247
- Recruiting
- The Catholic University Of Korea St. Vincent's Hospital
-
-
-
-
-
Auckland, New Zealand, 1124
- Recruiting
- Auckland City Hospital
-
-
-
-
-
Pozna?, Poland, 60-335
- Withdrawn
- Uniwersytecki Szpital Kliniczny w Poznaniu
-
-
-
-
-
Barcelona, Spain, 08025
- Withdrawn
- Hospital de la Santa Creu i Sant Pau
-
Madrid, Spain, 28033
- Withdrawn
- MD Anderson Cancer Center Madrid ? Espana
-
Madrid, Spain, 28034
- Withdrawn
- Hospital Universitario Ramon y Cajal
-
Madrid, Spain, 28036
- Withdrawn
- Clinica Universitaria Navarra (Madrid)
-
Sevilla, Spain, 41013
- Withdrawn
- Hospital Universitario Virgen del Rocío
-
Sevilla, Spain, 41013
- Withdrawn
- Hospital Universitario Virgen Macarena
-
Valencia, Spain, 46010
- Withdrawn
- Hospital Clinico Universitario de Valencia
-
-
Madrid
-
Pozuelo de Alarcon, Madrid, Spain, 28223
- Withdrawn
- NEXT Oncology-Hospital Quironsalud Madrid
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Withdrawn
- Clinica Universidad de Navarra
-
-
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Has Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1
- Has Life expectancy >= 12 weeks
- Adequate organ function
- Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).
Inclusion Criteria for Dose-Finding Stage:
- Histologically confirmed locally advanced or metastatic solid tumor that has progressed after at least one available standard therapy or for which approved standard therapy has proven to be ineffective or intolerable
Inclusion Criteria for Expansion Stage: NSCLC Cohort
- Histologically confirmed locally advanced or metastatic NSCLC
- Absence of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK)
- PD- L1 positive
- No prior systemic therapy for locally advanced or metastatic NSCLC
Inclusion Criteria for Expansion Stage: HNSCC Cohort
- Histologically confirmed recurrent, or metastatic HNSCC
- PD-L1 positive
- No prior systemic therapy for recurrent or metastatic HNSCC
Inclusion Criteria for Expansion Stage: BRAF WT melanoma Cohort
- Histologically confirmed locally advanced or metastatic or unresectable locally advanced cutaneous BRAF WT melanoma or melanomas of unknown primary that are non-mucosal and non -uveal that has progressed on or after treatment that included anti PD1 or anti PD-L1 therapy
Inclusion Criteria for Expansion Stage: Other Advanced or Metastatic Solid Tumors Cohort
- Histologically confirmed locally advanced or metastatic solid tumor that has progressed after at least one available standard therapy or for which approved standard therapy has proven to be ineffective or intolerable, standard therapy is considered inappropriate, or an investigational agent is a recognized standard of care
Exclusion Criteria:
- Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.
- Has leptomeningeal disease or carcinomatous meningitis
- Has uncontrolled hypertension
- Has left ventricular ejection fraction < institutional lower limit of normal or < 50%
- Has clinically significant history of liver disease including viral or other hepatitis, current alcohol abuse, or cirrhosis
- Has an active or history of autoimmune disease or immune deficiency including myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or multiple sclerosis. Participants with a history of autoimmune- related hypothyroidism on thyroid replacement hormone or with controlled Type I diabetes mellitus on a stable dose of an insulin regimen are eligible for this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose-finding Stage: GDC-1971
Participants will receive GDC-1971 tablet or capsule at assigned dose, orally once daily (QD) on Days 1-21 of each cycle, along with atezolizumab 1200 milligrams (mg) intravenous (IV) infusion once every 3 weeks (Q3W), until unacceptable toxicity or loss of clinical benefit.
A subset of participants will participate in evaluations regarding tablet versus (vs) capsule formulations.
|
Capsule or tablet administered orally.
Other Names:
Administered as IV infusion.
Other Names:
|
Experimental: Expansion Stage: GDC-1971
Participants will receive GDC-1971 orally at the assigned dose QD on Days 1-21 of each cycle and atezolizumab 1200 mg IV on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit.
A subset of participants will participate in evaluations regarding tablet vs capsule formulation, the effect of food and acid-reducing agents on GDC-1971.
|
Capsule or tablet administered orally.
Other Names:
Administered as IV infusion.
Other Names:
Administered orally as tablet or capsule in the acid-reducing agent assessment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of Participants With Adverse Events (AEs)
Time Frame: Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
Percentage of Participants With Clinically Significant Change From Baseline in Vital Signs
Time Frame: Baseline up to 30 days after final dose of study treatment (up approximately to 2.5 years)
|
Baseline up to 30 days after final dose of study treatment (up approximately to 2.5 years)
|
Percentage of Participants With Clinically Significant Change from Baseline in Clinical Laboratory Test Results
Time Frame: Baseline up to 30 days after final dose of study treatment (up approximately to 2.5 years)
|
Baseline up to 30 days after final dose of study treatment (up approximately to 2.5 years)
|
Percentage of Participants With Clinically Significant Change From Baseline in RR and QT Intervals as Measured by Electrocardiogram (ECG)
Time Frame: Baseline up to 30 days after final dose of study treatment (up approximately to 2.5 years)
|
Baseline up to 30 days after final dose of study treatment (up approximately to 2.5 years)
|
Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)
Time Frame: From Day 1 to Day 21 of Cycle 1 of the dose finding stage
|
From Day 1 to Day 21 of Cycle 1 of the dose finding stage
|
Plasma Concentration of GDC-1971
Time Frame: Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area Under the Concentration-Time Curve From Time 0 to 96 hours (AUC0-96 hr) Following GDC-1971 Capsule or Tablet Administration
Time Frame: Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
AUC From Time 0 to Infinity (AUCinf) Following GDC-1971 Capsule or Tablet Administration
Time Frame: Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
Cmax of GDC-1971 Following Capsule or Tablet Administration
Time Frame: Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
AUC 0-96 hr Following GDC-1971 Tablet Administration Under Fasted and Fed Conditions
Time Frame: Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
AUC inf Following GDC-1971 Tablet Administration Under Fasted and Fed Conditions
Time Frame: Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
Cmax of GDC-1971 Following Tablet Administration Under Fasted and Fed Conditions
Time Frame: Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
AUC 0-24 hr at Steady State Following GDC-1971 Tablet Administration and in Combination With Omeprazole
Time Frame: Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
Cmax at Steady State Following GDC-1971 Tablet Administration and in Combination With Omeprazole
Time Frame: Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
Objective Response Rate (ORR)
Time Frame: Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
Duration of Response (DOR)
Time Frame: Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
Progression Free Survival (PFS)
Time Frame: Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
PFS Rate
Time Frame: Month 6
|
Month 6
|
Overall Survival (OS) Rate
Time Frame: Months 6 and 12
|
Months 6 and 12
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GO43712
- 2021-006479-40 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States, Spain, Australia
-
University of AlbertaWithdrawnLocally Advanced Solid Tumors | Metastatic Solid TumorsCanada
Clinical Trials on GDC-1971
-
Hoffmann-La RocheCompletedSolid Tumor, Unspecified, AdultUnited States
-
Genentech, Inc.RecruitingColorectal Cancer | Non-Small Cell Lung CancerKorea, Republic of, Australia, United States, Canada
-
Daiichi Sankyo, Inc.CompletedPharmacokinetics | Tolerability | SafetyUnited Kingdom
-
Genentech, Inc.RecruitingColorectal Cancer | Non-Small Cell Lung Cancer | Advanced Solid TumorsUnited States, Korea, Republic of, Spain, United Kingdom, Brazil, Israel, New Zealand, Netherlands, Canada, Australia, Switzerland, Belgium, Italy, Norway, Poland, Hungary, Kenya, Russian Federation, Germany
-
Genentech, Inc.Completed
-
Genentech, Inc.Completed
-
Genentech, Inc.CompletedHealthy VolunteerUnited States
-
Stanford UniversityNational Cancer Institute (NCI); University Hospitals Cleveland Medical CenterCompletedRecurrent Skin Cancer | Basal Cell Carcinoma of the SkinUnited States
-
National Cancer Institute (NCI)Completed
-
Genentech, Inc.Completed